Global Oncology Bispecific CD3 Molecules Analytical Tool 2021: 67 Companies Plus Partners who are Today Developing 148 Drugs, 127 are in Active Development in Cancer Across 63 Different Targets
January 26, 2021 04:28 ET
|
Research and Markets
Dublin, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. There is a considerable and robust...
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
November 10, 2020 01:08 ET
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 10:13 ET
|
ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 04:13 ET
|
ImmunoPhotonics, Inc.
BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
April 29, 2020 08:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute
March 09, 2020 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
LSU Chemical Engineering Professor Receives NSF CAREER Award for Particle Transport Research
February 11, 2020 13:00 ET
|
LSU College of Engineering
BATON ROUGE, La., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Assistant Professor of Chemical Engineering Bhuvnesh Barti has been awarded the National Science Foundation’s CAREER Award for his research,...
Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
January 20, 2020 11:32 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark...
Vivos Inc. Provides 2019 Recap and Outlines 2020 Objectives
January 13, 2020 07:30 ET
|
Vivos Inc.
Richland WA, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2019 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2020, I think it is...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 04, 2019 08:00 ET
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...